Menu Search
Equities

BioArctic AB

BIOA B:STO

BioArctic AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)142.30
  • Today's Change-2.20 / -1.52%
  • Shares traded217.42k
  • 1 Year change-33.88%
  • Beta0.1283
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in SEK

The 7 analysts offering 12 month price targets for BioArctic AB have a median target of 286.00, with a high estimate of 350.00 and a low estimate of 270.00. The median estimate represents a 100.98% increase from the last price of 142.30.
High146.0%350.00
Med101.0%286.00
Low89.7%270.00

Earnings history & estimates in SEK

On Aug 29, 2024, BioArctic AB reported 2nd quarter 2024 losses of -0.77 per share. This result was in line with the consensus of the 3 analysts following the company and exceeded last year's 2nd quarter results by 33.62%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+7.94%
BioArctic AB reported annual 2023 earnings of 2.59 per share on Feb 14, 2024.
Average growth rate+8.04%
More ▼

Revenue history & estimates in SEK

BioArctic AB (publ) had 2nd quarter 2024 revenues of 49.80m. This bettered the 47.60m consensus of the 4 analysts covering the company. This was 87.34% below the prior year's 2nd quarter results.
Average growth rate+1,939.94%
BioArctic AB (publ) had revenues for the full year 2023 of 616.00m. This was 169.83% above the prior year's results.
Average growth rate+228.85%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.